Thorne HealthTech, Inc.

NasdaqGS:THRN Aktierapport

Börsvärde: US$550.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Thorne HealthTech Förvaltning

Förvaltning kriterier kontrolleras 3/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Paul Jacobson

Verkställande direktör

US$4.1m

Total ersättning

VD-lön i procent12.96%
Anställning som VD13.8yrs
Ägande av VDn/a
Ledningens genomsnittliga anställningstid9.8yrs
Styrelsens genomsnittliga mandatperiod8.4yrs

Senaste uppdateringar av ledningen

Recent updates

Analysartikel • Aug 12

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Thorne HealthTech, Inc. ( NASDAQ:THRN ) defied analyst predictions to release its second-quarter results, which were...
Analysartikel • Jun 07

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

With a price-to-earnings (or "P/E") ratio of 25.5x Thorne HealthTech, Inc. ( NASDAQ:THRN ) may be sending very bearish...
Analysartikel • Dec 17

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...
Seeking Alpha • Sep 09

Thorne HealthTech Grows But Faces Macro Headwinds

Summary Thorne HealthTech went public in September 2021, raising approximately $70 million in a U.S. IPO. The company designs and sells wellness and nutraceutical products worldwide. THRN has produced revenue growth but faces inflationary pressures, the loss of a significant distributor in Europe and the stock may be fully valued here. I'm on Hold for THRN for the near term. A Quick Take On Thorne HealthTech Thorne HealthTech, Inc. (THRN) went public in September 2021, raising approximately $70 million in gross proceeds from an IPO that priced at $10.00 per share. The firm designs and sells wellness and nutraceutical products under its brands Thorne and Onegevity. Given the risks of continued inflationary pressures and a macroeconomic slowdown combined with a potentially fully valued stock at its current price of around $5.00 per share, I'm on Hold for THRN in the near term. Thorne HealthTech Overview New York, NY-based Thorne was founded to develop premium wellness products for consumers utilizing its Onegevity platform to discover and develop new products. The firm sells products directly and also has a product subscription program Management is headed by Chief Executive Officer Paul Jacobson, who has been with the firm since 2010 when he acquired Thorne Research and was previously co-founder of Onegevity Health, which was acquired by Thorne. THRN sells its products through a direct to consumer channel [DTC] as well as through online ecommerce sites such as Amazon, distributors and through connected health professionals. The company also gathers personalized testing data and has plans to use this information for additional services to practitioners. Thorne HealthTech's Market & Competition According to a 2021 market research report by Grand View Research, the global market for dietary supplements was an estimated $140.3 billion in 2020 and is forecast to reach $271 billion by 2028. This represents a forecast CAGR of 8.6% from 2021 to 2028. The main drivers for this expected growth are a growing consumer awareness of personal health and wellness products as well as increased R&D from product makers. Also, below is a chart showing the historical and projected future market size by ingredient for dietary supplements in the U.S.: U.S. Dietary Supplements Market (Grand View Research) Major competitive or other industry participants include: Nestle Health Science Metagenics Hims 23and Me Livongo Schrodinger SEMA4 Numerous other nutritional supplement companies Thorne HealthTech's Recent Financial Performance Total revenue by quarter has grown according to the following chart: 9 Quarter Total Revenue (Seeking Alpha) Gross profit by quarter has followed approximately the same trajectory as that of total revenue: 9 Quarter Gross Profit (Seeking Alpha) Selling, G&A expenses as a percentage of total revenue by quarter rose substantially in the most recent quarter: 9 Quarter Selling, G&A % Of Revenue (Seeking Alpha) Operating income by quarter has turned negative in Q2 2022: 9 Quarter Operating Income (Seeking Alpha) Earnings per share (Diluted) have turned into negative territory in Q2 2022: 9 Quarter Earnings Per Share (Seeking Alpha) (All data in above charts is GAAP) Since its IPO, THRN's stock price has fallen 38.4% vs. the U.S. S&P 500 index' drop of around 9.9%, as the chart below indicates: Stock Price Since IPO (Seeking Alpha) Valuation And Other Metrics For Thorne HealthTech Below is a table of relevant capitalization and valuation figures for the company: Measure [TTM] Amount Enterprise Value / Sales 1.31 Revenue Growth Rate 28.5% Net Income Margin 0.97 GAAP EBITDA % 1.8% Market Capitalization $267,930,000 Enterprise Value $272,780,000 Operating Cash Flow $1,190,000 Earnings Per Share (Fully Diluted) $0.04 (Source - Seeking Alpha) Below is an estimated DCF (Discounted Cash Flow) analysis of the firm's projected growth and earnings: Discounted Cash Flow - Thorne (GuruFocus) Assuming generous DCF parameters, the firm's shares would be valued at approximately $5.13 versus the current price of $5.01, indicating they are potentially currently fully valued, with the given earnings, growth and discount rate assumptions of the DCF. As a reference, a relevant partial public comparable would be larger firm Glanbia plc (GLAPF, GLAPY); shown below is a comparison of their primary valuation metrics: Metric Glanbia plc Thorne HealthTech Variance Enterprise Value / Sales 0.79 1.31 65.8% Revenue Growth Rate 23.7% 28.5% 20.3% Net Income Margin 5.4% 0.97 1689.7% Operating Cash Flow $104,990,000 $1,190,000 -98.9% (Source - Seeking Alpha) A full comparison of the two companies' performance metrics may be viewed here. Commentary On Thorne HealthTech In its last earnings call (Source - Seeking Alpha), covering Q2 2022's results, management highlighted improvements in its sales mix and the effect of increased prices and scale growth as offsets to inflationary pressures on its cost of sales. Notably, the firm's Pro and B2B sales channels produced strong growth year-over-year, excluding the loss of a distributor related to the conflict in Ukraine, which it estimates reduced Q2 revenue by "as much as $6.9 million."
Seeking Alpha • Aug 23

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Thorne HealthTech (NASDAQ:THRN) said its blood collection device OneDraw was certified in Japan as a medical device after being cleared by the Pharmaceutical and Medical Devices Agency (PMDA). "We appreciate the help from our partners in Japan because we believe this will create many additional opportunities to expand our relationships globally, while we continue to move forward on a similar regulatory pathway in the United States," said Thorne CEO Paul Jacobson. The company noted that OneDraw is already approved by the FDA as a class 2 medical device, and it has a European Conformity mark for supervised use by health-care professionals to collect blood samples to measure HbA1c for monitoring the long-term control of blood sugar (glucose) in diabetic individuals.
Seeking Alpha • Aug 09

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Thorne HealthTech press release (NASDAQ:THRN): Q2 Non-GAAP EPS of -$0.05 (vs. $0.22 Y/Y). Revenue of $56.1M (+30.8% Y/Y). FY22 guidance revised to net sales of $235M to $242M (vs. consensus of $247.13M) and EPS of of $0.36 to $0.39 (vs. consensus of $0.34). Shares -1.47% AH.
Seeking Alpha • Jun 05

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Nutraceutical companies will perform well during the next decade, even during a recession. DIY health trends are on the rise. Thorne HealthTech is well-positioned to benefit from these trends.
Analysartikel • Mar 23

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Thorne HealthTech, Inc.'s ( NASDAQ:THRN ) strong earnings report was rewarded with a positive stock price move. We have...
Seeking Alpha • Jan 11

Thorne HealthTech: Good Potential At A Low Price

The market oversold Thorne shares. The company is growing at double-digit rates. It has strong positioning and enormous market potential. If marketing efficiency remains the same in the coming years, revenue will grow exponentially. This scenario is highly likely because the indicator is increasing. Despite the stage of aggressive growth, Thorne is already a profitable company. We expect the company to continue growing and improve profitability. The company is trading at a significant discount to its fair market value. PEG ratio is less than 1.

Analys av ersättningar till VD

Hur har Paul Jacobson:s ersättning förändrats jämfört med Thorne HealthTech:s resultat?
DatumTotal ersättningLönFöretagets resultat
Jun 30 2023n/an/a

US$20m

Mar 31 2023n/an/a

US$10m

Dec 31 2022US$4mUS$530k

US$16m

Sep 30 2022n/an/a

US$6m

Jun 30 2022n/an/a

US$3m

Mar 31 2022n/an/a

US$9m

Dec 31 2021US$13mUS$530k

US$4m

Sep 30 2021n/an/a

-US$822k

Jun 30 2021n/an/a

-US$1m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$759kUS$530k

-US$3m

Ersättning vs marknad: Paul s total kompensation ($USD 4.09M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 2.65M ).

Ersättning vs inkomst: Ersättningen från Paul har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Paul Jacobson (68 yo)

13.8yrs
Anställning
US$4,088,000
Kompensation

Mr. Paul F. Jacobson Co-Founded Thorne HealthTech, Inc. in 2010 and has been its Chief Executive Officer and Director since 2010. He is Chairman of Thorne HealthTech, Inc. He was Interim Principal Financi...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Paul Jacobson
Co-Founder13.8yrsUS$4.09minga uppgifter
William McCamy
Presidentno dataUS$1.35minga uppgifter
Saloni Varma
CFO & Directorless than a yearUS$463.20k0.032%
$ 173.4k
Thomas McKenna
COO & Director13.8yrsUS$2.89minga uppgifter
Scott Hurth
Chief Technology Officer9.8yrsinga uppgifteringa uppgifter
Nathan Price
Chief Scientific Officer & CEO of Onegevityno datainga uppgifteringa uppgifter
Thomas Wilson
VP & Head of Investor Relationsno datainga uppgifteringa uppgifter
Kim Pearson
General Counsel28.8yrsinga uppgifteringa uppgifter
Michelle Crow
Chief Marketing Officer5.9yrsinga uppgifteringa uppgifter
Rob Monteleone
Senior VP of Professional Salesno datainga uppgifteringa uppgifter
Bodi Zhang
Chief Strategy Officerno datainga uppgifteringa uppgifter
Stephen Phipps
Chief Innovation Officer2.8yrsinga uppgifteringa uppgifter
9.8yrs
Genomsnittlig anställningstid
45.5yo
Genomsnittlig ålder

Erfaren ledning: THRN s ledningsgrupp är erfaren och erfaren ( 9.8 års genomsnittlig anställning).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Paul Jacobson
Co-Founder13.8yrsUS$4.09minga uppgifter
Saloni Varma
CFO & Director2.1yrsUS$463.20k0.032%
$ 173.4k
Thomas McKenna
COO & Director13.8yrsUS$2.89minga uppgifter
Riccardo Braglia
Independent Director11.8yrsinga uppgifter0%
$ 0
Sarah Kauss
Independent Director2.1yrsUS$469.45k0.021%
$ 114.6k
Toshitaka Inuzuka
Independent Director5yrsinga uppgifter0%
$ 0
8.4yrs
Genomsnittlig anställningstid
58.5yo
Genomsnittlig ålder

Erfaren styrelse: THRN s styrelse anses vara erfaren ( 8.4 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2023/10/18 10:27
Aktiekurs vid dagens slut2023/10/13 00:00
Intäkter2023/06/30
Årlig intjäning2022/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Thorne HealthTech, Inc. bevakas av 5 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Bryan SpillaneBofA Global Research
Susan AndersonCanaccord Genuity
Elizabeth AndersonEvercore ISI